See more : Kids Smile Holdings Inc. (7084.T) Income Statement Analysis – Financial Results
Complete financial analysis of Gelesis Holdings, Inc. (GLS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gelesis Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SDCL EDGE Acquisition Corporation (SEDA-UN) Income Statement Analysis – Financial Results
- Shalag Industries Ltd (SALG.TA) Income Statement Analysis – Financial Results
- Bank of Montreal (BMO) Income Statement Analysis – Financial Results
- Carney Technology Acquisition Corp. II (CTAQ) Income Statement Analysis – Financial Results
- Gecoss Corporation (9991.T) Income Statement Analysis – Financial Results
Gelesis Holdings, Inc. (GLS)
About Gelesis Holdings, Inc.
Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | 25.77M | 11.19M |
| Cost of Revenue | 27.56M | 9.98M |
| Gross Profit | -1.79M | 1.20M |
| Gross Profit Ratio | -6.95% | 10.75% |
| Research & Development | 18.61M | 12.87M |
| General & Administrative | 42.21M | 18.26M |
| Selling & Marketing | 56.92M | 52.78M |
| SG&A | 99.14M | 71.04M |
| Other Expenses | 2.27M | 2.27M |
| Operating Expenses | 120.02M | 86.18M |
| Cost & Expenses | 147.57M | 96.16M |
| Interest Income | 0.00 | 0.00 |
| Interest Expense | 991.00K | 1.36M |
| Depreciation & Amortization | 7.59M | 4.44M |
| EBITDA | -121.81M | -80.53M |
| EBITDA Ratio | -443.25% | -719.97% |
| Operating Income | -121.81M | -84.97M |
| Operating Income Ratio | -472.72% | -759.70% |
| Total Other Income/Expenses | 66.51M | -8.36M |
| Income Before Tax | -55.30M | -93.33M |
| Income Before Tax Ratio | -214.62% | -834.42% |
| Income Tax Expense | 480.00K | 17.00K |
| Net Income | -55.78M | -93.35M |
| Net Income Ratio | -216.48% | -834.57% |
| EPS | -0.79 | -16.34 |
| EPS Diluted | -0.79 | -16.34 |
| Weighted Avg Shares Out | 70.30M | 5.71M |
| Weighted Avg Shares Out (Dil) | 70.30M | 5.71M |
Royal Mail's sister business GLS to buy 20% stake in Greece's ACS for $80 million
Parcel services firm GLS, the international sister business to the UK's Royal Mail, has agreed to buy a 20% stake in Greece's ACS for 74 million euros ($80.06 million), their parent International Distribution Services said on Monday.
Royal Mail, GLS need sizable investments soon, billionaire suitor Kretinsky says
Royal Mail and its international parcels network GLS need sizable, almost immediate investments to defend market share and face shifting market trends, Czech billionaire Daniel Kretinsky told Reuters on Wednesday after the group's owner agreed to a 3.57 billion pound...
Cell Reports Medicine Publication Demonstrates How Gelesis' Oral Therapeutic Hydrogel Promotes Weight Loss and Metabolic Health by Targeting the Gut-Liver Axis in Pre-Clinical Studies
BOSTON--(BUSINESS WIRE)---- $GLS #earnings--A new paper published today in Cell Reports Medicine suggests that weight loss resulting from Gelesis' superabsorbent hydrogel treatment is not only a result of its space-occupying properties; the mechanical composition and structure of the material may...
Gelesis Holdings, Inc. (GLS) Q3 2022 Earnings Call Transcript
Gelesis Holdings, Inc. (NYSE:GLS ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Anna Kate Heller - IR Yishai Zohar - Founder and CEO Elliot Maltz – CFO Conference Call Participants Daniel Grosslight - Citi...
Gelesis Reports Third Quarter 2022 Results
BOSTON--(BUSINESS WIRE)--Gelesis Holdings, Inc. (NYSE: GLS) (“Gelesis” or the “Company”), the maker of Plenity for weight management, today reported financial results for the third quarter of 2022. Plenity is a novel orally administered, FDA-cleared weight management therapy that helps people...
Dr. Frank Greenway to Present Data from the LIGHT-UP Study with Gelesis' Oral Hydrogel Treatment GS200 at Obesity Week
BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today announced Dr. Frank Greenway will give an oral presentation at Obesity Week in San Diego, on Wednesday, November 2 at 4:00pm PDT.
Clinical Data from the LIGHT-UP Study Presented at the International Congress of Endocrinology Suggests New Gelesis Oral Hydrogel May Improve Insulin Sensitivity and Favorably Impact Metabolic Syndrome
BOSTON–(BUSINESS WIRE)–Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today released a poster presentation at the International Congress of Endocrinology in Singapore. The LIGHT-UP study evaluated the safety and efficacy of GS200,...
Gelesis Holdings, Inc. (GLS) CEO Yishai Zohar on Q2 2022 Results - Earnings Call Transcript
Gelesis Holdings, Inc. (NYSE:GLS ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Anna Heller - IR Yishai Zohar - Founder & CEO Elliot Maltz - CFO David Pass - COO & CCO Conference Call...
Gelesis Reports Second Quarter 2022 Results
BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, today reported financial results for the second quarter of 2022. “We are seeing both consumers and clinicians embracing Plenity, with continued growth in both of our distribution channels. We...
Gelesis Holdings' (GLS) CEO Yishai Zohar on Q1 2022 Results - Earnings Call Transcript
Gelesis Holdings, Inc. (NYSE:GLS ) Q1 2022 Earnings Conference Call May 1, 2022 4:30 PM ET Company Participants Yishai Zohar – Founder and Chief Executive Officer Elliot Maltz – Chief Financial Officer David Pass – Chief Operating and Commercial Officer...
Source: https://incomestatements.info
Category: Stock Reports